JNJ Johnson & Johnson (JNJ) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0000200406
Congress · 3Form 144 · 5
Insider buyers, 180 days
0
Funds added, last quarter
2,298
13F, latest reported quarter
Conversions, 180 days
9
Codes C/M, not in net · $26.3M priced
What the filings say about JNJ
Insiders, 180 days
-$70.2M net sold
6 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
3 bought · 4 sold
Latest: purchase, 2026-09-08
Planned sales (Form 144), 90 days
$61.8M
5 notices
Johnson & Johnson insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, JOHNSON & JOHNSON insiders sold a net $70.2M of stock across 251 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Feb 20, 2026.
- The trade is 43.5% of the 25,447 shares held after it.
- 3 other insiders sold within 30 days.
- 2,298 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, WW Chair, MedTech Schmid Timothy sold about $3.0M of JNJ on Sep 2, 2026; 3 other insiders sold within 30 days and 2,298 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Feb 20, 2026.
- The trade is 88.5% of the 25,447 shares held after it.
- 3 other insiders sold within 30 days.
- 2,298 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, WW Chair, MedTech Schmid Timothy sold about $6.2M of JNJ on Sep 2, 2026; 3 other insiders sold within 30 days and 2,298 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Sep 4, 2025.
- The trade is 7.7% of the 194,451 shares held after it.
- 4 other insiders sold within 30 days.
- 2,298 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, WWC. Innovative Medicine Taubert Jennifer L sold about $4.0M of JNJ on Aug 17, 2026; 4 other insiders sold within 30 days and 2,298 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Aug 5, 2026.
- The trade is 5.5% of the 378,282 shares held after it.
- 4 other insiders sold within 30 days.
- 2,298 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and Chairman of the Board Duato Joaquin sold about $5.5M of JNJ on Aug 13, 2026; 4 other insiders sold within 30 days and 2,298 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Aug 5, 2026.
- The trade is 37.1% of the 275,967 shares held after it.
- 4 other insiders sold within 30 days.
- 2,298 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and Chairman of the Board Duato Joaquin sold about $26.7M of JNJ on Aug 13, 2026, the largest insider sale at the company on our record; 4 other insiders sold within 30 days and 2,298 funds added in the latest 13F quarter.251 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$70.2M over 180 days
-$62.0M over 90 days
below 96% of Pharma & Biotech
Congress
3 members bought in the last year
more than 90% of Pharma & Biotech
Funds
2,298 funds bought in last quarter
the highest in Pharma & Biotech
Revenue
+6.0% year over year
more than 54% of Pharma & Biotech
Margin
28.5% net margin
more than 90% of Pharma & Biotech
Buybacks
$6.0B repurchased, FY to 2026-09-27
the highest in Pharma & Biotech
Short interest
0.9% of the float short (float per yahoo 2026-10-26) · 3.3 days to cover · settled 2026-09-30
below 74% of Pharma & Biotech
What changed in the last 30 days
Oct 5Rep. Lloyd Doggett sold $1.0K to $15K, disclosed 27 days after the trade
Why it matters
House members report a bracket, not an exact amount, and have 45 days to do it; the trade is weeks old when it becomes public.
Watch JNJ
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+39.1%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns JNJ: institutional holders (13F)
13F holdings, latest reported quarter
212,098,264 sh
$53.9B
157,226,374 sh
$39.9B
133,776,025 sh
$34.0B
64,370,816 sh
$16.3B
58,301,609 sh
$15.1B
Congress trades in JNJ
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2026-09-08 · disclosed 27 days later
$1,001 - $15,000
Sold 2026-08-27 · disclosed 16 days later
$1,001 - $15,000
Sold 2026-07-30 · disclosed 15 days later
$1,001 - $15,000
Sold 2026-06-29 · disclosed 16 days later
$1,001 - $15,000
Bought 2026-06-09 · disclosed 27 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
JNJ planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Schmid Timothy
Filed 2026-09-02
$9.2M
Taubert Jennifer L
Filed 2026-08-17
$4.0M
Duato Joaquin
Filed 2026-08-13
$32.2M
Forminard Elizabeth
Filed 2026-08-06
$4.1M
Joaquin Duato
Filed 2026-08-05
$12.4M
JNJ mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares U.S. Pharmaceuticals ETF
$255.5M position · as of 2026-06-30
22.4%
State Street(R) Health Care Select Sector SPDR(R) ETF
$4.3B position · as of 2026-06-30
10.6%
iShares U.S. Healthcare ETF
$362.5M position · as of 2026-07-31
10.2%
Portfolio Building Block World Pharma and Biotech Index ETF
$92.0M position · as of 2026-07-31
9.7%
JNL/Mellon Healthcare Sector Fund
$251.9M position · as of 2026-06-30
9.4%
PROFUND VP HEALTH CARE
$3.3M position · as of 2026-06-30
9.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Government contracts
Award ceilings over the contract's life, subsidiaries included.
Not annual revenue (USASpending.gov).
Department Of Health And Human Services
JANSSEN - TPOM OT AGREEMENT · 2018-09-21
$56.0M
Federal awards ≥ $25M in the last 90 days, matched via the SAM.gov parent registry
Executive pay vs shareholder return · A. Gorsky
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$32.8M
$68.3M
$12.5M
+52%
+89%
2024
$24.3M
$17.0M
$11.2M
+3%
+48%
2023
$28.4M
$13.8M
$12.5M
+8%
+37%
2022
$13.1M
$18.9M
$8.0M
+18%
+37%
2021
$26.7M
$39.4M
$12.5M
+11%
+26%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $70.2M sold by insiders over 180 days, 2,298 funds added last quarter, 3 House member(s) bought in 12 months, disclosed weeks after the trade, $61.8M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
JNJ financials
Revenue growth
+6.0%
XBRL, annual
Net margin
28.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$99.3B
four quarters, 2025-09-29 to 2026-09-27
Revenue, TTM JNJ
| FY Dec 2025 | $94.2B |
| FY Dec 2024 | $88.8B |
| FY Dec 2023 | n/a |
| FY Jan 2023 | n/a |
| FY Jan 2022 | $93.8B |
| Sep 2026 | $25.4B |
| Jun 2026 | $25.3B |
| Mar 2026 | $24.1B |
| Dec 2025 | $24.6B |
| Sep 2025 | $24.0B |
| Jun 2025 | $23.7B |
| Mar 2025 | $21.9B |
| Dec 2024 | $22.5B |
At each fiscal year end
Single quarter
Net margin, TTM
+16.2%
net income over revenue, 2025-09-29 to 2026-09-27
Net margin, TTM JNJ
| FY Dec 2025 | +28.5% |
| FY Dec 2024 | +15.8% |
| FY Dec 2023 | n/a |
| FY Jan 2023 | n/a |
| FY Jan 2022 | +22.3% |
| Sep 2026 | +0.8% |
| Jun 2026 | +21.9% |
| Mar 2026 | +21.8% |
| Dec 2025 | +20.8% |
| Sep 2025 | +21.5% |
| Jun 2025 | +23.3% |
| Mar 2025 | +50.2% |
| Dec 2024 | +15.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$20.6B
operating cash flow minus capex, 2025-09-29 to 2026-09-27
Free cash flow, TTM JNJ
| FY Dec 2025 | $19.7B |
| FY Dec 2024 | $19.8B |
| FY Dec 2023 | $18.2B |
| FY Jan 2023 | $17.2B |
| FY Jan 2022 | $19.8B |
| Sep 2026 | $6.4B |
| Jun 2026 | $7.3B |
| Mar 2026 | $1.5B |
| Dec 2025 | $5.5B |
| Sep 2025 | $8.0B |
| Jun 2025 | $2.8B |
| Mar 2025 | $3.4B |
| Dec 2024 | $5.4B |
At each fiscal year end
Single quarter
Debt to equity
0.55x
long-term 2026-09-27 plus current 2026-09-27; equity 2026-09-27
Debt to equity JNJ
| FY Dec 2025 | 0.59x |
| FY Dec 2024 | 0.51x |
| FY Dec 2023 | 0.43x |
| FY Jan 2023 | 0.52x |
| FY Jan 2022 | 0.46x |
| Sep 2026 | 0.55x |
| Jun 2026 | 0.58x |
| Mar 2026 | 0.68x |
| Dec 2025 | 0.59x |
| Sep 2025 | 0.58x |
| Jun 2025 | 0.65x |
| Mar 2025 | 0.67x |
| Dec 2024 | 0.51x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.59x
TTM operating cash flow over long-term 2026-09-27 plus current 2026-09-27
Cash flow to debt JNJ
| FY Dec 2025 | 0.51x |
| FY Dec 2024 | 0.66x |
| FY Dec 2023 | 0.78x |
| FY Jan 2023 | 0.53x |
| FY Jan 2022 | 0.69x |
| Sep 2026 | 0.59x |
| Jun 2026 | 0.56x |
| Mar 2026 | 0.42x |
| Dec 2025 | 0.51x |
| Sep 2025 | 0.53x |
| Jun 2025 | 0.45x |
| Mar 2025 | 0.47x |
| Dec 2024 | 0.66x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+20.0%
TTM net income over average of 2025-09-28 and 2026-09-27
Return on equity JNJ
| FY Dec 2025 | +35.0% |
| FY Dec 2024 | +20.1% |
| FY Dec 2023 | +48.3% |
| FY Jan 2023 | +23.8% |
| FY Jan 2022 | +30.4% |
| Sep 2026 | +20.0% |
| Jun 2026 | +25.7% |
| Mar 2026 | +26.4% |
| Dec 2025 | +35.0% |
| Sep 2025 | +33.6% |
| Jun 2025 | +30.2% |
| Mar 2025 | +29.4% |
| Dec 2024 | +20.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+8.2%
TTM net income over average of 2025-09-28 and 2026-09-27
Return on assets JNJ
| FY Dec 2025 | +14.1% |
| FY Dec 2024 | +8.1% |
| FY Dec 2023 | +19.8% |
| FY Jan 2023 | +9.7% |
| FY Jan 2022 | +11.7% |
| Sep 2026 | +8.2% |
| Jun 2026 | +10.7% |
| Mar 2026 | +10.7% |
| Dec 2025 | +14.1% |
| Sep 2025 | +13.5% |
| Jun 2025 | +12.1% |
| Mar 2025 | +11.9% |
| Dec 2024 | +8.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on invested capital JNJ
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Jan 2023 | n/a |
| FY Jan 2022 | n/a |
| Sep 2026 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
Return on capital employed JNJ
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Jan 2023 | n/a |
| FY Jan 2022 | n/a |
| Sep 2026 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
40.03x
close 2026-10-23 over four quarters of diluted EPS, 2025-09-29 to 2026-09-27
P/E, trailing JNJ
| FY Dec 2025 | 18.81x |
| FY Dec 2024 | 25.05x |
| FY Dec 2023 | 11.35x |
| FY Jan 2023 | 26.21x |
| FY Jan 2022 | 21.90x |
| Sep 2026 | 41.16x |
| Jun 2026 | 29.54x |
| Mar 2026 | 27.83x |
| Dec 2025 | 18.81x |
| Sep 2025 | 17.35x |
| Jun 2025 | 16.30x |
| Mar 2025 | 18.21x |
| Dec 2024 | 25.05x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$662.8B
market value at close 2026-10-23 on 2026-10-15 shares, plus long-term 2026-09-27 plus current 2026-09-27, minus cash 2026-09-27
Enterprise value JNJ
| FY Dec 2025 | $528.5B |
| FY Dec 2024 | $361.8B |
| FY Dec 2023 | $384.8B |
| FY Jan 2023 | $488.6B |
| FY Jan 2022 | $469.7B |
| Sep 2026 | $681.4B |
| Jun 2026 | $641.6B |
| Mar 2026 | $612.8B |
| Dec 2025 | $528.5B |
| Sep 2025 | $460.4B |
| Jun 2025 | $398.9B |
| Mar 2025 | $407.9B |
| Dec 2024 | $361.8B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+3.2%
TTM free cash flow over market value at close 2026-10-23
FCF yield JNJ
| FY Dec 2025 | +3.9% |
| FY Dec 2024 | +5.7% |
| FY Dec 2023 | +4.8% |
| FY Jan 2023 | +3.7% |
| FY Jan 2022 | +4.4% |
| Sep 2026 | +3.2% |
| Jun 2026 | +3.6% |
| Mar 2026 | +3.1% |
| Dec 2025 | +3.9% |
| Sep 2025 | +4.5% |
| Jun 2025 | +5.1% |
| Mar 2025 | +5.2% |
| Dec 2024 | +5.7% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -36%, PEG needs growth
PEG, trailing JNJ
| FY Dec 2025 | 0.21x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 0.11x |
| FY Jan 2023 | n/a |
| FY Jan 2022 | 0.52x |
| Sep 2026 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | 0.21x |
| Sep 2025 | 0.24x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2023-01 | |
|---|---|---|---|---|
| Revenue | $94.2B | $88.8B | $85.2B | $94.9B |
| Gross profit | $63.9B | $61.4B | $58.6B | $55.4B |
| Net income | $26.8B | $14.1B | $35.2B | $17.9B |
| EPS (diluted) | 11.03 | 5.79 | 13.72 | 6.73 |
| Operating cash flow | $24.5B | $24.3B | $22.8B | $21.2B |
| Cash | $19.7B | $24.1B | $21.9B | $12.9B |
| Long-term debt | $39.4B | $30.7B | $25.9B | $26.9B |
| Buybacks | $6.0B | $2.4B | $5.1B | $6.0B |
SEC XBRL, fiscal years, as known on 2026-10-27
JNJ Stock Sonar score 6/7 axes
Find similar shapesCompareJNJ ranks highest on profitability (88th percentile) and financial health (59th), and lowest on insider conviction (1st), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
JNJ filings, in plain words
Are Johnson & Johnson insiders buying or selling JNJ?
In the 180 days to 2026-10-27, Johnson & Johnson insiders were net sellers, a net $70.2M across purchases and sales reported on Form 4, by 6 sellers.
Have members of Congress traded JNJ?
Yes. In the year to 2026-10-27, 3 House members disclosed buying JNJ and 4 House members disclosed selling it; the latest on record is a purchase by Lloyd Doggett dated 2026-09-08.
Are there planned insider sales of JNJ?
Yes. 5 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $61.8M of stock; the latest, by Schmid Timothy, was filed 2026-09-02.
Read the full summary
In the 180 days to 2026-10-27, Johnson & Johnson insiders were net sellers of JNJ, a net $70.2M across purchases and sales reported on Form 4 by 6 sellers. None of the 11 insider sales was flagged as made under a Rule 10b5-1 plan. In the year to 2026-10-27, 3 members of Congress disclosed buying JNJ and 4 members disclosed selling it; the latest on record is a purchase by Lloyd Doggett dated 2026-09-08. Insiders filed 5 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $61.8M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
